mechanistic target of rapamycin kinaseGenealiases: FRAP · FRAP1 · FRAP2 · RAFT1 · RAPT1 · SKS
Q-omics provides the consensus-scored MTOR profile across patient tissues and cancer cell-line models. MTOR expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MTOR is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, MTOR RNA expression shows 20,494 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and KIRC as cancer lineages where MTOR shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTOR — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTOR survival associations across molecular data types. MTOR RNA expression shows survival associations in the most cancer types (24), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTOR RNA expression–survival associations across cancer types. High MTOR expression shows unfavorable associations in ACC, LUSC, LGG and BLCA, but favorable associations in KIRC and SCLC. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MTOR RNA expression.
This table summarizes MTOR tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for MTOR. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTOR shows lower tumor expression in KIRC and KICH and higher tumor expression in BLCA, HNSC, LIHC and LUSC. The KIRC box plot shows higher MTOR RNA expression in normal versus tumor tissue (log2 FC = −1.064, t-test p < 0.001).
This table shows molecular features associated with MTOR in patient tissues and cancer cell lines. In patient samples, MTOR shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MTOR RNA and mutation anchors are most strongly linked to RNA-expression features, especially in CNS, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BLOOD_Leukemia.
